Oxford BioTherapeutics has entered a multi‑year collaboration with Bristol Myers Squibb to discover and develop novel T‑cell ...

Bayer has received MHRA approval for Kerendia (finerenone) for adults in the UK with symptomatic chronic heart failure and a left ventricular ejection fraction of 40% or above. Th ...

For decades, MASLD has been described as a ‘silent’ condition because it rarely presents with dramatic liver specific ...

GLP-1 therapies have now advanced far beyond their origins. Originally developed as treatments for type 2 diabetes, they have ...

Kainova Therapeutics has dosed the first patient in the European expansion of its DOMISOL phase 1/2 trial of DT 7012, a ...

For decades, progress in IVF has been driven by improvements in process efficiency rather than advances in biology. Clinics ...

Ardena has announced the appointment of Paul Edwards as Chief People Officer. He will lead Ardena’s global people strategy, ...

A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases. A British inquiry into the use of chemotherapy ...

New study to test Sema3A antibody in rare genetic kidney disease Evotec SE has announced that partner Bayer AG has initiated a phase 2 clinical study of BAY 3401016, a monoclonal antibody targeting ...